glp 1 agonists in development GLP-1 Market Exclusive Research Report 2025 Mapping the effectiveness and risks

The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Youve likely heard about the incredible results of GLP-1 (glucagon-like peptide-1) medications, such as semaglutide, liraglutide, and tirzepatide, for

Heres what research and medical experts say they canand cantdo.

Results show broad benefits with a reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimers disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions

Novo Nordisk research has explored how GLP-1 medications like Wegovy can quieten food noise, resulting in a healthier lifestyle, according to respondents.